Erasca, Inc. (ERAS) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Erasca Inc (ERAS) PT Lowered to $3 at Goldman Sachs
August 13, 2024 1:52 PM EDTGoldman Sachs analyst Chris Shibutani lowered the price target on Erasca Inc (NASDAQ: ERAS) to $3.00 (from $4.00) while maintaining a Buy rating.
The analyst comments "Post the company's prior announcement in May of a strategic reset with subsequent financings, the company's 2Q24 operational and program updates (see... More
Erasca Inc (ERAS) PT Raised to $6 at H.C. Wainwright
August 13, 2024 6:11 AM EDTH.C. Wainwright analyst Andres Y. Maldonado raised the price target on Erasca Inc (NASDAQ: ERAS) to $6.00 (from $5.00) while maintaining a Buy rating.
The analyst comments "What to expect from the newly initiated SEACRAFT-2 study. Erasca recently announced the initiation of the global SEACRAFT-2 Phase 3 trial to evaluate the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib for patients with NRAS-mutant melanoma. Our positive outlook on this program is... More
